Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health
Location: University of Birmingham, Edgbaston, Birmingham UK
Full time starting salary is normally in the range £36,636 to £46,049 with potential progression once in post to £48,822
Grade: 7
Full Time, Fixed Term contract up to April 2027
Closing date: 11th February 2026
We are seeking a highly motivated Postdoctoral Research Fellow to join NIHR-funded research programme evaluating the use of apixaban thromboprophylaxis to prevent venous thromboembolism (VTE) in ambulatory lung cancer patients undergoing systemic anticancer treatment (SACT) [Thrombo-STOP trial].
This role will focus on conducting the process evaluation within the wider study, exploring how apixaban prophylaxis is delivered in routine care, and how it is experienced by patients and clinicians. The insights generated from this work will directly inform the feasibility, acceptability, and scalability of thromboprophylaxis in lung cancer, and help shape future approaches to supportive cancer care.
You will be based within the Department of Applied Health Sciences and work closely with Dr Agnieszka Ignatowicz and wider team, collaborating with a multidisciplinary team across academic and clinical settings. This role offers the opportunity to be part of a nationally leading research and clinical collaboration, with prospects for career development, high-impact publications, and the chance in shaping care for people living with lung cancer.
Venous thromboembolism (VTE) is common in lung cancer and leads to poorer quality of life, increased healthcare costs, and higher morbidity and mortality. Risk is particularly high in patients receiving systemic anticancer therapy.
Anticoagulation has been shown to reduce VTE, but routine thromboprophylaxis is not current standard care for this population. Subcutaneous low molecular weight heparin can reduce risk, but is inconvenient for patients. Apixaban, a direct oral anticoagulant (DOAC), is easier to administer, has a good safety profile, and is widely used in other clinical contexts.
This trial will assess whether six months of apixaban (2.5mg BD) reduces VTE in ambulatory lung cancer patients starting SACT.
Tagged as: Life Sciences
Research Fellow Position The School of Chemistry at the University of Birmingham is a vibrant and thriving academic community, with...
ApplyPostdoctoral Research Associate School of Chemistry Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in...
ApplyResearch Fellow The University of Birmingham is seeking to recruit a Research Fellow to make a significant contribution to an...
ApplyResearch Fellow Position School of Physics and Astronomy, College of Engineering and Physical Sciences Location: University of Birmingham, Edgbaston, Birmingham...
ApplyJob Title Postdoctoral Research Associate in Condensed Matter Physics Job Description Position Details School of Physics and Astronomy Location: University...
ApplyResearch Associate Position The recruited research associate will be working on the NERC Environmental Challenges grant “P-FASE: Advancing And Integrating...
ApplyPlease visit edzz.fa.em3.oraclecloud.com.
Don't forget to mention that you found the position on jobRxiv!
